1st lung cancer vaccine trials launch, powered by COVID mRNA technology

The mRNA revolution continues. Just a few years after mRNA vaccines proved their efficacy against COVID-19, scientists are now turning their attention to lung cancer.

The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries, including the United States and the United Kingdom. This vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of…